Whitehawk Therapeutics, Inc. WHWK

NAS: WHWK | ISIN: US00032Q1040 29/05/2026

4,720 USD (-1,26%)

(-1,26%) 29/05/2026

Grafiek Whitehawk Therapeutics, Inc.

Grafiek Whitehawk Therapeutics, Inc.

1 dag1d -1,26%
1 week1w -1,05%
1 maand1m 17,71%
3 maanden3m 45,68%
6 maanden6m 108,85%
1 jaar1j 171,26%
5 jaar5j 133,66%

Whitehawk Therapeutics, Inc. in het nieuws

Toon enkel gratis nieuws

30 mei 2026 · Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 · Persbericht

28 mei 2026 · Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference · Persbericht

21 mei 2026 · Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload · Persbericht

20 mei 2026 · Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit · Persbericht

15 mei 2026 · Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum · Persbericht

13 mei 2026 · Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing · Persbericht

7 mei 2026 · Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights · Persbericht

20 april 2026 · Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026 · Persbericht

16 april 2026 · Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series · Persbericht

10 april 2026 · Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026 · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe